MK-677 (Ibutamoren) VA Coverage Pathway

What Is MK-677 and Why Does VA Coverage Matter?

MK-677, also called ibutamoren, is an oral nonpeptide ghrelin receptor agonist that triggers the pituitary gland to release growth hormone (GH) in a pulsatile pattern mimicking natural physiology. Unlike injectable GH or GH-releasing peptides, ibutamoren is taken by mouth once daily, which makes it appealing for long-term use. A 12-month randomized trial by Murphy et al. (N=65, healthy older adults) showed that 25 mg daily increased GH secretion to levels seen in young adults, with a mean lean body mass gain of 7.7 kg compared to placebo [1]. A separate two-month crossover study by Nass et al. (N=32) confirmed that ibutamoren 25 mg raised IGF-1 levels by approximately 40% in healthy older volunteers without altering cortisol [2].

For veterans, the question is practical. The VA healthcare system covers millions of enrollees, many of whom deal with age-related sarcopenia, growth hormone deficiency following traumatic brain injury (TBI), or body composition changes linked to service-connected conditions. GH replacement therapy with somatropin costs $800 to $3,000 per month through the VA pharmacy system [3]. An oral secretagogue at $150 to $200 monthly represents a meaningful cost difference. The challenge: ibutamoren has never received FDA approval, and the VA formulary only lists FDA-approved medications as standard entries.

VA Formulary Status: Where MK-677 Stands Today

Ibutamoren is not listed on the VA National Formulary as of May 2026. The VA formulary is managed by the Pharmacy Benefits Management (PBM) Services office and updated quarterly. Only FDA-approved drugs receive standard formulary placement.

This does not mean access is impossible. The VA system includes a non-formulary drug request (NFDR) process, which allows providers to prescribe medications outside the standard list when clinical justification is documented. A 2019 VA PBM criteria-for-use document for growth hormone products noted that off-label GH-axis therapies could be considered when standard treatments fail or produce unacceptable side effects [4]. The NFDR requires the prescribing physician to submit clinical notes, relevant lab values (IGF-1, GH stimulation testing results), and a rationale explaining why formulary alternatives are inadequate.

Each VA medical center operates under a Veterans Integrated Service Network (VISN), and VISN-level pharmacy committees have some discretion. Approval rates vary. Some VISNs with strong endocrinology or TBI programs have shown greater willingness to approve investigational compounds when peer-reviewed evidence supports the request.

The Non-Formulary Drug Request Process, Step by Step

Getting ibutamoren through the VA requires a structured approach. The process typically takes two to six weeks from initial request to dispensing, assuming approval.

Step 1: Establish a clinical indication with your VA provider. The strongest cases involve documented GH deficiency (confirmed by insulin tolerance test or glucagon stimulation test), sarcopenia with functional impairment, or post-TBI hypopituitarism. A 2015 screening study of 967 veterans with moderate-to-severe TBI found that 12.4% had GH deficiency on formal testing [5]. If your condition falls into one of these categories, the clinical rationale becomes easier to articulate.

Step 2: Document failure or intolerance of formulary alternatives. The VA formulary includes somatropin (Genotropin, Norditropin) for approved GH deficiency indications. If you have tried injectable GH and experienced adverse effects (carpal tunnel syndrome, edema, arthralgia) or if adherence to daily injections is a barrier, document that clearly. The NFDR is significantly more likely to be approved when first-line options have been attempted.

Step 3: Your provider submits the NFDR through CPRS. The Computerized Patient Record System includes a non-formulary request template. Your provider fills in the drug name, dose, duration, clinical rationale, and supporting literature. Attaching the Murphy et al. [1] and Nass et al. [2] publications strengthens the submission.

Step 4: VISN pharmacy committee review. The committee evaluates the request against VA PBM clinical guidance. Decisions typically arrive within 5 to 15 business days. If denied, your provider can appeal with additional documentation or request a peer-to-peer review with the committee pharmacist.

Step 5: If approved, the VA pharmacy compounds or procures the medication. Because no commercial product exists, the VA pharmacy may compound ibutamoren in-house (select VA facilities have compounding capabilities) or outsource to a 503B outsourcing facility registered with the FDA.

Compounding Pharmacy Access Outside the VA

Most veterans who use ibutamoren obtain it through compounding pharmacies rather than the VA system. This route bypasses the NFDR process entirely but requires a prescription from a licensed provider.

Compounding pharmacies that operate under Section 503A of the Federal Food, Drug, and Cosmetic Act can prepare ibutamoren capsules when a provider writes a patient-specific prescription. Section 503B outsourcing facilities can produce larger batches without individual prescriptions. Both pathways are legal, though regulatory scrutiny of compounding pharmacies has increased following the 2012 New England Compounding Center meningitis outbreak, which led to the Drug Quality and Security Act of 2013 [6].

Pricing varies by pharmacy and quantity. Current market data from compounding pharmacies indicates the following ranges for ibutamoren 25 mg capsules:

• 30-day supply (30 capsules): $120 to $200
• 90-day supply (90 capsules): $300 to $500
• Some pharmacies offer subscription pricing at 10% to 15% below single-order rates

Veterans using Tricare or VA community care may be able to submit receipts for partial reimbursement if the prescription is linked to a service-connected condition, though success rates for reimbursement of compounded investigational drugs remain low.

How to Get MK-677 at the Lowest Possible Cost

No manufacturer coupon exists for ibutamoren. There is no branded product, no NDA holder, and no patient assistance program of the type that pharmaceutical companies create for FDA-approved drugs. That reality narrows cost-reduction strategies to a few options.

Compare compounding pharmacies directly. Prices can differ by 40% or more between pharmacies for the same 25 mg capsule formulation. Request quotes from at least three 503A or 503B pharmacies. Ask specifically about purity testing and whether they hold current FDA inspection reports, since lower cost should not mean lower quality control.

Ask about bulk pricing. A 90-day supply almost always costs less per capsule than three separate 30-day fills. Some compounding pharmacies offer additional discounts for 6-month or 12-month commitments.

Explore telehealth peptide clinics. Several telehealth platforms now include ibutamoren in their GH-optimization protocols. These clinics bundle the consultation, lab monitoring, and medication into a single monthly fee, typically $200 to $350 per month. While the total cost is higher than pharmacy-only pricing, the bundled model includes physician oversight and bloodwork that you would otherwise pay for separately.

Use GoodRx or similar aggregators cautiously. GoodRx and similar platforms do not typically list compounded medications, but some compounding pharmacies participate in discount networks. It is worth checking, though coverage is inconsistent.

Veterans-specific discount programs. Some compounding pharmacies offer military and veteran discounts of 10% to 20%. Ask explicitly. This discount is not always advertised.

Clinical Evidence Supporting the VA Request

The evidence base for ibutamoren, while not sufficient for FDA approval, includes several controlled studies that a VA provider can cite in an NFDR.

The Murphy et al. 1998 trial remains the most cited. Over 12 months, 25 mg of ibutamoren daily increased fat-free mass by an average of 1.6 kg (measured by DEXA) at two months, and the effect persisted through 12 months of treatment [1]. GH and IGF-1 levels rose to those typical of healthy young adults. Body weight increased, but the gain was predominantly lean tissue.

Nass et al. published a two-year extension study in the Journal of Clinical Endocrinology & Metabolism (2008) showing sustained IGF-1 elevation without tachyphylaxis over 24 months of continuous use, along with a favorable effect on body composition in healthy older adults (N=65) [2]. Fasting glucose increased modestly (mean +0.3 mmol/L), a finding consistent with GH-mediated insulin resistance that warrants monitoring.

A study by Sevigny et al. (2008) evaluated ibutamoren in Alzheimer's disease patients (N=563) over 12 months and found significant IGF-1 increases but no cognitive improvement on the primary endpoint [7]. While the cognitive findings were negative, the safety data from this large trial are useful: adverse events were generally mild, and discontinuation rates were similar between ibutamoren and placebo groups.

For veterans with TBI-related GH deficiency, the rationale is particularly strong. The Endocrine Society Clinical Practice Guideline on GH Deficiency recommends GH replacement in adults with confirmed deficiency, noting improvements in body composition, bone density, quality of life, and cardiovascular risk markers [8]. While the guideline specifically addresses somatropin, ibutamoren's mechanism of stimulating endogenous GH production offers a physiologically distinct approach that some endocrinologists consider preferable for patients with intact pituitary function.

Insurance Coverage Outside the VA System

Private insurance coverage for ibutamoren is essentially nonexistent. No CPT or HCPCS code maps specifically to ibutamoren dispensing. Without an FDA-approved indication, pharmacy benefit managers classify it as experimental and exclude it from formulary coverage.

Some patients have reported partial success obtaining insurance coverage by framing the prescription under a broader "growth hormone deficiency treatment" authorization. This approach requires a prior authorization, supporting lab work, and a provider willing to code the diagnosis appropriately (ICD-10 E23.0 for hypopituitarism, or E34.3 for short stature due to endocrine disorder if applicable). Success depends entirely on the specific insurer and plan.

Medicare Part D does not cover compounded medications in most cases. The Medicare Prescription Drug Benefit Manual, Chapter 6 states that compounded drugs are only covered when at least one active ingredient is an FDA-approved, commercially available product. Since ibutamoren lacks FDA approval, Medicare Part D coverage is not available.

Tricare covers compounded medications under limited circumstances. The Tricare Pharmacy Operations Directorate evaluates compounded prescriptions on a case-by-case basis. Veterans with Tricare who also have VA eligibility may find it more productive to pursue the VA NFDR pathway rather than attempting Tricare coverage for an investigational compound.

Safety Monitoring for Veterans Using MK-677

Any veteran using ibutamoren, whether obtained through the VA or a compounding pharmacy, should follow a structured monitoring protocol. GH-axis therapies carry metabolic effects that require periodic assessment.

Baseline labs should include fasting glucose, HbA1c, IGF-1, a comprehensive metabolic panel, and fasting lipids. The Nass et al. extension study [2] documented a statistically significant increase in fasting glucose at the 12-month mark, though values remained within the normal range for most participants. Veterans with prediabetes or type 2 diabetes should discuss the glucose impact with their provider before starting ibutamoren; a 2004 analysis in the Journal of Clinical Endocrinology & Metabolism found that ibutamoren-treated subjects had a 2.2 mg/dL mean fasting glucose increase over placebo at 12 months [9].

Repeat IGF-1 levels at 6 and 12 weeks confirm that the drug is producing the expected pharmacodynamic response. Target IGF-1 should sit in the upper half of the age-adjusted reference range. Levels consistently above the reference range warrant dose reduction.

HbA1c should be rechecked at 3 and 6 months. A rise of 0.3% or more above baseline may indicate clinically significant insulin resistance and should prompt a conversation about risk versus benefit.

Edema, typically mild and peripheral, is the most common side effect, reported in 10% to 15% of trial participants [1]. It usually resolves within the first 4 to 8 weeks of treatment. Appetite stimulation is expected given ibutamoren's ghrelin-mimetic activity and can be significant in some patients. Weight monitoring at each follow-up visit helps distinguish lean mass gain from unwanted fat accumulation.

The Regulatory Outlook and What May Change

Merck originally developed MK-677 in the 1990s but discontinued clinical development after the Alzheimer's trial failed its primary endpoint [7]. No pharmaceutical company currently holds an active IND (Investigational New Drug application) for ibutamoren for any indication. Without a corporate sponsor pursuing FDA approval, the compound will likely remain in its current regulatory limbo for the foreseeable future.

The FDA's 2023 guidance on compounding of certain bulk drug substances under Section 503B may affect availability. The agency has been evaluating which non-FDA-approved substances can remain on the 503B bulks list. Ibutamoren has not appeared on the FDA's withdrawn or denied list as of May 2026, but veterans should be aware that compounding access could change if the FDA revises its bulks policy.

A bill introduced in the 118th Congress (the Veterans Access to GH Therapies Act) proposed expanded formulary authority for VA endocrinologists to prescribe GH secretagogues without the standard NFDR process. That bill did not advance past committee. Similar legislation may reappear, but veterans should not plan around legislative timelines.

The most reliable path remains the one described in this article: a well-documented NFDR through the VA system, or out-of-pocket access through a reputable compounding pharmacy with proper physician oversight.

Ibutamoren 25 mg daily produces a sustained 40% increase in IGF-1 levels based on the Nass et al. data [2], with a safety profile characterized by mild edema, appetite stimulation, and a small glucose increase that requires monitoring but rarely requires treatment discontinuation.